Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and <scp>VEGFR</scp> ‐ <scp>TKIs</scp> in Real‐World Patients With Advanced Renal Cell Carcinoma
With a minimum of 3 years of follow-up, IO-TKI demonstrated feasible effectiveness and manageable safety in patients with advanced RCC in the real world. More effective treatment strategies and novel therapeutic targets are needed for patients with non-clear-cell RCC.
Authors
- Nanaka Katsurayama
- Hiroaki Shimmura
- Kazuhiko Yoshida
- Hironori Fukuda
- Junpei Iizuka
- Yuki Nemoto
- Takayuki Nakayama
- Shinsuke Mizoguchi
- Tsunenori Kondo
- Yasunobu Hashimoto
- Hiroki Ishihara
- Toshio Takagi
Institutions
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
- Noguchi Hospital (JP)
- Saiseikai Ibaraki Hospital (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1111/iju.70444
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00